5-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine | 1319067-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 5-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine
• 英文别名: 5-trifluoromethyl-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine；5-trifluoromethyl-[1,2,4]triazolo[1,5-a]pyridine-2-yl-amine
• CAS: 1319067-64-5
• 化学式: C₇H₅F₃N₄
• 分子量: 202.139
• InChiKey: PSSQTQSLTKVMJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine 在 对甲苯磺酸 、 potassium iodide 、 sodium nitrite 作用下， 以 水 、 乙腈 为溶剂， 反应 18.0h， 以58.6%的产率得到2-iodo-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine
  参考文献：
  名称：

  [EN] BICYCLIC LACTAMS AND METHODS OF USE THEREOF
  [FR] LACTAMES BICYCLIQUES ET LEURS MÉTHODES D'UTILISATION

  摘要：

  公开号：

  WO2017004500A9
• 作为产物：
  描述：

  2-氨基-6-(三氟甲基)吡啶 在 盐酸羟胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 反应 31.0h， 生成 5-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine
  参考文献：
  名称：

  [EN] BICYCLIC LACTAMS AND METHODS OF USE THEREOF
  [FR] LACTAMES BICYCLIQUES ET LEURS MÉTHODES D'UTILISATION

  摘要：

  公开号：

  WO2017004500A9

文献信息

• [EN] GAMMA SECRETASE MODULATERS<br/>[FR] MODULATEURS DE GAMMA-SECRÉTASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011092272A1

  公开（公告）日：2011-08-04

  The invention relates to compounds of formula ( I ) wherein R1/R1' are independently from each other hydrogen, halogen, lower alkoxy or cyano; R2 is lower alkyl, halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by OR, =0, -C(O)O-lower alkyl, -C(O)NH-lower alkyl, cyano, CH2-O-lower alkyl, cycloalkyl, NRR'or is -O-(CH2)o-phenyl optionally substituted by halogen, or is -(CH2)o-phenyl optionally substituted by one, two or three substituents, selected from halogen, -(CH2)o-cyano, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, C(O)H, -CH2-NH2-, -CH2-NH-C(O)O-lower alkyl, -CH2-NH-C(O)-lower alkyl, -CH2-NH-lower alkyl, -CH2-NH-S(O)2-lower alkyl, lower alkoxy or by lower alkoxy substituted by halogen, or is -(CH2)o-cycloalkyl, or is -(CH2)o-heterocycloalkyl which is optionally substituted by halogen, CF3, lower alkyl, -CH2CN, -C(O)-lower alkyl, -C(O)O-lower alkyl or S(O)2-lower alkyl, or is heteroaryl selected from the group consisting of furanyl, pyrazinyl, pyridinyl, benzooxazolyl or benzoimidazolyl which are optionally substituted by lower alkyl, or is 4-methyl-3,4-dihydro-2H-benzo[l,4]oxazine R and R' are independently from each other hydrogen or lower alkyl, and o is 0 or 1; R3 may occur once or twice and is lower alkyl; A is Formula a), b), c), d), e), f), h), i), j) and Formula k); R2' is hydrogen, lower alkyl, lower alkyl substituted by halogen, C(O)-lower alkyl, S(O)2-lower alkyl or phenyl optionally substituted by halogen; hetaryl is a 5 or 6 membered N, S or O-containing heteroaryl group; n is O, 1, 2 or 3; if n is 2 or 3, R2 may be the same or not; or to pharmaceutically active acid addition salts thereof. The present compounds of formula ( I ) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi- infarct dementia, dementia pugilistica and Down syndrome.

  该发明涉及以下式（I）的化合物，其中R1/R1'分别独立地为氢、卤素、较低的烷氧基或氰基；R2为较低的烷基、卤素、较低的烷氧基、卤素取代的较低烷基、卤素取代的较低烷氧基、取代的较低烷基OR、=0、-C(O)O-较低烷基、-C(O)NH-较低烷基、氰基、CH2-O-较低烷基、环烷基、NRR'或为-O-(CH2)o-苯基，可选择地取代为卤素，或为-(CH2)o-苯基，可选择地取代为一个、两个或三个取代基，选自卤素、-(CH2)o-氰基、较低烷基、卤素取代的较低烷基、羟基取代的较低烷基、C(O)H、-CH2-NH2-、-CH2-NH-C(O)O-较低烷基、-CH2-NH-C(O)-较低烷基、-CH2-NH-较低烷基、-CH2-NH-S(O)2-较低烷基、较低烷氧基或取代的较低烷氧基，或为-(CH2)o-环烷基，或为-(CH2)o-杂环烷基，可选择地取代为卤素、CF3、较低烷基、-CH2CN、-C(O)-较低烷基、-C(O)O-较低烷基或S(O)2-较低烷基，或为杂芳基，选自呋喃基、吡嗪基、吡啶基、苯并噁唑基或苯并咪唑基，可选择地取代为较低烷基，或为4-甲基-3,4-二氢-2H-苯并[l,4]噁啉，R和R'分别独立地为氢或较低烷基，o为0或1；R3可能出现一次或两次，为较低烷基；A为式a)、b)、c)、d)、e)、f)、h)、i)、j)和式k)；R2'为氢、较低烷基、卤素取代的较低烷基、C(O)-较低烷基、S(O)2-较低烷基或可选择地取代为卤素的苯基；hetaryl为5或6成员的含氮、硫或氧的杂芳基；n为O、1、2或3；如果n为2或3，R2可能相同也可能不同；或其药用活性酸盐。该式（I）的化合物是淀粉样蛋白β的调节剂，因此，它们可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病、遗传性淀粉样脑出血症，荷兰型（HCHWA-D），多梗死性痴呆、拳击性痴呆和唐氏综合征。
• GAMMA SECRETASE MODULATORS
  申请人：Baumann Karlheinz

  公开号：US20110190269A1

  公开（公告）日：2011-08-04

  The invention relates to compounds of formula wherein R 1 , R 1′ , R 2 , R 3 , n, A, and hetaryl are defined herein or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  该发明涉及以下式的化合物 其中R 1 ，R 1′ ，R 2 ，R 3 ，n，A和hetaryl在此处定义，或其药用活性酸盐。式I的这些化合物是淀粉样蛋白β的调节剂，因此它们可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病，遗传性脑出血伴有淀粉样变性，荷兰型（HCHWA-D），多梗死性痴呆，拳击性痴呆和唐氏综合征。
• BRIDGED PIPERIDINE DERIVATIVES
  申请人：Baumann Karlheinz

  公开号：US20120225884A1

  公开（公告）日：2012-09-06

  The present invention relates to compounds of formula I hetaryl I, hetaryl II, R 1 , R 2 , R 3 , Y, m, and o or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  本发明涉及式Ihetaryl I、hetaryl II、R1、R2、R3、Y、m和o的化合物，或其药用活性酸盐。式I的这些化合物是淀粉样蛋白β的调节剂，因此它们可能对治疗或预防与大脑中β-淀粉样蛋白沉积相关的疾病有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病、遗传性淀粉样脑出血、荷兰型（HCHWA-D）、多梗死性痴呆、拳击性痴呆和唐氏综合征。
• [EN] BRIDGED PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPÉRIDINE PONTÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012116965A1

  公开（公告）日：2012-09-07

  The present invention relates to compounds of formula (l); hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N; hetaryl II is a six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, or N, wherein at least one ring is aromatic in nature; R1 is lower alkyl, lower alkoxy, lower alkyl substituted by halogen or halogen; R2 is lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, cycloalkyl substituted by lower alkyl or lower alkyl substituted by halogen, or is lower alkyl substituted by hydroxy, or is furyl, or is O-benzyl, (CH2)p-phenyl, optionally substituted by halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkyl or by cyano; R3 is hydrogen or lower alkyl; Y is (CH2)n-, -CH2OCH2-, -CH2O-, CH2S-, -CH2SCH2- and is bonded to two of the ring carbon atoms, bonding being to either the ring carbon atoms a and b or the ring carbon atoms c and d; p is 0 or 1; m is 0, 1 or 2; if m is 2 then R1 may be the same or different; -75- n is 2 or 3; o is 0, 1 or 2, if o is 2, then R2 may be the same or different; or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimers disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  本发明涉及以下式（l）的化合物；hetaryl I 是一个含有1至3个杂原子（S或N）的五元或六元杂芳基团；hetaryl II 是一个含有1至3个杂原子（S或N）的六元杂芳基团，或者是一个含有1至4个杂原子（S或N）的两元环系统，其中至少一个环具有芳香性质；R1 是低碳基、低烷氧基、被卤素取代的低烷基或卤素；R2 是低碳基、被卤素取代的低烷基、卤素、低烷氧基、被低烷基取代的环烷基、或被卤素取代的低烷基，或者是被羟基取代的低烷基，或是呋喃基，或是O-苄基，（CH2）p-苯基，可选择地被卤素、低烷氧基、被卤素取代的低烷基、低烷基或氰基取代；R3 是氢或低碳基；Y 是（CH2）n-、-CH2OCH2-、-CH2O-、CH2S-、-CH2SCH2-，与两个环碳原子结合，结合到环碳原子a和b或环碳原子c和d之一；p 为0或1；m 为0、1或2；若m为2，则R1 可相同或不同；n 为2或3；o 为0、1或2，若o为2，则R2 可相同或不同；或其药用酸盐。本发明的式I化合物是淀粉样蛋白β的调节剂，因此可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病、家族性脑出血伴淀粉样蛋白沉积、荷兰型（HCHWA-D）、多梗塞性痴呆、拳击性痴呆和唐氏综合征。
• [EN] CBL-B MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE CBL-B ET LEURS UTILISATIONS
  申请人：NIMBUS CLIO INC

  公开号：WO2022272248A1

  公开（公告）日：2022-12-29

  The invention provides compounds, compositions thereof, and methods of using the same for the inhibition of Cb1-b, and the treatment of a variety of Cb1-b-mediated diseases, disorders or conditions, associated with modulating the immune system implicating Cb1-b. Compounds are also useful for the study of Cb1-b enzymes in biological and pathological phenomena; the study of ubiquitination occurring in bodily tissues; and the comparative evaluation of new Cb1-b inhibitors or other regulators of cell cycle, DNA repair, differentiation, and innate and adaptive immunity in vitro or in vivo.

  本发明提供了用于抑制 Cb1-b 和治疗各种 Cb1-b 介导的疾病、失调或病症的化合物、其组合物和使用方法，这些疾病、失调或病症与调节涉及 Cb1-b 的免疫系统有关。化合物还可用于研究生物和病理现象中的 Cb1-b 酶；研究身体组织中发生的泛素化；以及比较评估体外或体内新的 Cb1-b 抑制剂或细胞周期、DNA 修复、分化以及先天性和适应性免疫的其他调节剂。